The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes

Diabetic Medicine

Volumn 30, Issue 11, 2013, Pages 1305-1313

  Quilliam, B J ^a   Ozbay, A B ^a   Sill, B E ^b   Kogut, S J ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONYLUREA; TRIMETHOPRIM; WARFARIN;

ADULT; ARTICLE; COMORBIDITY; DATA BASE; DIABETIC PATIENT; DRUG USE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALGORITHMS; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 84885909644     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12217     Document Type: Article

References (36)

1. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998; 352: 837-853.
2. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005; 118: 27S-34S.
3. Gregoire JP, Sirois C, Blanc G, Poirier P, Moisan J. Persistence patterns with oral antidiabetes drug treatment in newly treated patients-a population-based study. Value Health 2010; 13: 820-828.
4. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004; 27: 2149-2153.
5. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004; 10: 144-151.
6. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140-1147.
7. Bonds DE, Miller ME, Dudl J, Feinglos M, Ismail-Beigi F, Malozowski S et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: secondary analysis of the ACCORD clinical trial data. BMC Endocr Disord 2012; 12: 5.
8. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
9. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality of life and impact on costs. J Med Econ 2011; 14: 646-655.
10. Adamson DM, Chang S, Hansen LG. Health Research Data for the Real World: The Marketscan Databases. New York: Thompson Healthcare, 2008.
11. Thomson Reuters HI. MarketScan User Guide. Ann Arbor: Thomson Reuters, 2007.
12. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
13. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 2004; 27: B10-21.
14. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004; 27: 2800-2805.
15. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006; 12: 466-471.
16. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002; 25: 1015-1021.
17. Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004; 38: 1357-1362.
18. Kim N, Agostini JV, Justice AC. Refill adherence to oral hypoglycemic agents and glycemic control in veterans. Ann Pharmacother 2010; 44: 800-808.
19. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008; 8: 4.
20. Meduru P, Helmer D, Rajan M, Tseng C, Pogach L, Sambamoorthi U. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. J Gen Intern Med 2007; 22: S408-418.
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
22. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25: 245-254.
23. Walter RM Jr. Hypoglycemia: still a risk in the elderly. Geriatrics 1990; 45: 69-71, 74-75.
24. Barnett AH, Cradock S, Fisher M, Hall G, Hughes E, Middleton A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract 2010; 64: 1121-1129.
25. Aspinall SL, Good CB, Jiang R, McCarren M, Dong D, Cunningham FE. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009; 49: 402-408.
26. Gabriely I, Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. Cleve Clin J Med 2004; 71: 335-342.
27. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34: S11-61.
28. Strachan MW, Ewing FM, Frier BM, Harper A, Deary IJ. Food cravings during acute hypoglycaemia in adults with Type 1 diabetes. Physiol Behav 2004; 80: 675-682.
29. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
30. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
31. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf 2009; 32: 409-418.
32. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35: S11-63.
33. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir S. Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study. J Eval Clin Pract 2010; 16: 1124-1128.
34. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study Group. Lancet 1998; 352: 854-865.
35. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
36. Jonas D, Van Scoyoc E, Gerrald K, Wines R, Amick H, Triplette M et al. Drug Class Review: Newer Diabetes Medications, TZDs and Combinations: Final Original Report. Portland: Oregon Health and Science University, 2011.